Rakovina Therapeutics Presents AI-Discovered CNS-Penetrant ATR/mTOR Dual Inhibitors at Neuro-Oncology Meeting
核心洞察
Rakovina Therapeutics (搜索) showcased preclinical data on novel ATR/mTOR (搜索) dual inhibitors designed using Variational AI (搜索)'s Enki™ generative AI platform at the 2025 Society for Neuro-Oncology Annual Meeting.
The AI-discovered compounds demonstrate superior CNS penetration compared to current clinical ATR inhibitors and show greater than 50% ATR inhibition at 1 µM concentration.
These dual-pathway inhibitors specifically target PTEN (搜索)-deficient tumors by simultaneously blocking ATR-mediated DNA damage response and mTOR (搜索)-driven survival signaling pathways.
Rakovina Therapeutics (搜索) Inc. presented compelling preclinical data on its AI-discovered CNS-penetrant ATR/mTOR (搜索) dual inhibitors at the 2025 Society for Neuro-Oncology Annual Meeting in Honolulu, Hawaii. The Vancouver-based biopharmaceutical company showcased novel compounds designed using Variational AI (搜索)'s Enki™ generative AI platform that address critical limitations of current brain cancer therapies.
Novel Dual-Pathway Targeting Approach
The poster presentation, titled "Discovery and development of a novel CNS-penetrating ATR inhibitor: Dual inhibition of ATR and mTOR (搜索) in PTEN (搜索)-deficient tumors," highlighted the discovery of compounds engineered to modulate two well-established cancer-driving pathways that have never before been combined in a single therapeutic agent. These molecules were specifically designed to cross the blood-brain barrier and reach tumor cells within the central nervous system, supporting their potential relevance in primary brain cancers and cancers with high risk of brain metastasis.
The compounds were engineered with a mechanistic rationale to co-target ATR and mTOR (搜索), two pathways on which PTEN (搜索)-deficient tumors are highly dependent. By simultaneously blocking ATR-mediated DNA damage response and mTOR-driven survival signaling, these CNS-penetrant inhibitors have the potential to overcome key resistance mechanisms in PTEN-deficient cancers and deliver therapeutic effects not achievable with ATR-only agents.
Superior Performance Metrics
Rakovina's findings demonstrated that the AI-discovered ATR+mTOR (搜索) inhibitors achieve meaningful CNS penetration, addressing a key limitation of current clinical ATR inhibitors, which have poor CNS distribution. In direct comparisons, multiple Rakovina compounds showed greater than 50% ATR inhibition at 1 µM and exhibited equal or greater enzymatic potency than leading ATR inhibitors ceralasertib, tuvusertib, and elimusertib, while maintaining similar PIKK-family selectivity.
PTEN Deficiency as Therapeutic Target
PTEN (搜索) is one of the most frequently lost tumor-suppressor genes in human cancer and serves as a key brake on the PI3K/AKT/mTOR (搜索) signaling pathway that governs cell growth, metabolism, and survival. Its loss promotes unchecked proliferation, genomic instability, therapy resistance, and aggressive tumor progression, making PTEN-deficient tumors particularly challenging to treat with conventional therapies.
AI-Enabled Drug Discovery Platform
The research leverages Variational AI (搜索)'s Enki™ generative AI platform to design and optimize compounds with favorable pharmacologic properties. This AI-accelerated approach enables rapid identification and optimization of next-generation candidates designed to address limitations of first-generation inhibitors.
"Our participation reflects Rakovina's ongoing efforts to develop first-in-class DNA-damage response inhibitors designed to reach the brain," said Prof. Mads Daugaard, President and Chief Scientific Officer of Rakovina Therapeutics (搜索). "By combining AI-accelerated medicinal chemistry with the world-class infrastructure at the University of British Columbia's Vancouver Prostate Centre, we are advancing next-generation therapies targeting ATR and PARP1 pathways aimed at improving outcomes for patients with aggressive and treatment-resistant brain cancers."
The company has established a pipeline of distinctive DNA-damage response inhibitors with the goal of advancing one or more drug candidates into human clinical trials in collaboration with pharmaceutical partners.